Complementary to small molecules, α-helical peptides modeled on Vgll4 are delivered via PEG–PLA nanoliposomes to extend systemic exposure (circulation half‐life increased from 0.6 h to 3.2 h) and boost tumor accumulation by 2.5-fold in murine HNSCC models, while markedly reducing hepatotoxicity and nephrotoxicity (Liu et al., 2019). Here, VGLL4 is linked to neoplasm.